The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®)

References

• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–1785
   PubMed Web of Science ®Google Scholar
• De Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10: S93–S96, Suppl. 2
   PubMed Web of Science ®Google Scholar
• Dezube B. J. Safety assessment: DoxilR (Doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. Doxil Clinical Series, Gardiner-Caldwell Syner Med, Califon, NJ 1996; Volume I: 1–8
   Google Scholar
• Alberts D. S., Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54: 30–45, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Skubitz K. M., Skubitz A. P. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998; 9: 45–50
   PubMed Web of Science ®Google Scholar
• Hugli T. E. Structure and function of anaphylatoxins. Spring Semin Immunopathol 1984; 7: 193–219
   PubMed Web of Science ®Google Scholar
• Liszewski K., Atkinson J. P. The complement system. Fundamental Immunology, Third Edition, W. E. Paul. Raven Press, Ltd., New York 1993; 917–939
   Google Scholar
• Cheung A. K., Parker C. J., Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994; 46: 1680–7
   PubMed Web of Science ®Google Scholar
• Skroeder N. R., Jacobson S. H., Lins L. E., Kjellstrand C. M. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994; 18: 880–887
   PubMed Web of Science ®Google Scholar
• Skroeder N. R., Kjellstrand P., Holmquist B., Kjellstrand C. M., Jacobson S. H. Individual differences in biocompatibility responses to hemodialysis. Int J Artif Organs 1994; 17: 521–530
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wassef N. M., Rudolph A. S., Alving C. R. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys Acta 1996; 1285: 127–130
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wassef N. M., Hartman K. R., Rudolph A. S., Alving C. R. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 1997; 37: 150–159
   PubMed Web of Science ®Google Scholar
• Szebeni J., Spielberg H., Cliff R. O., Wassef N. M., Rudolph A. S., Alving C. R. Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin: Inhibition by soluble complement receptor type 1. Art Cells Blood Subs and Immob Biotechnol 1997; 25: 379–392
   PubMedGoogle Scholar
• Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998; 15: 57–88
   PubMed Web of Science ®Google Scholar
• Szebeni J., Fontana J. L., Wassef N. M., Mongan P. D., Morse D. S., Dobbins D. E., Stahl G. L., Bünger R., Alving C. R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99: 2302–2309
   PubMed Web of Science ®Google Scholar
• Szebeni J., Alving C. R. Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1999; 27: 23–41
   PubMed Web of Science ®Google Scholar
• Szebeni J., Baranyi B., Savay S., Bodo M., Morse D. S., Basta M., Stahl G. L., Bunger R., Alving C. R. Liposome-induced pulmonary hypertension in pigs: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol 2000; 279: H1319–H1328
   PubMed Web of Science ®Google Scholar
• Marceau F., Lundberg C., Hugli T. E. Effects of anaphylatoxins on circulation. Immunopharmacol 1987; 14: 67–84
   PubMed Web of Science ®Google Scholar
• Rabinovici R., Rudolph A. S., Feuerstein G. Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ Shock 1989; 29: 115–132
   PubMedGoogle Scholar
• Rabinovici R., Rudolph A. S., Yue T.-L., Feuerstein G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ Shock 1990; 31: 431–445
   PubMedGoogle Scholar
• Rabinovici R., Rudolph A. S., Ligler F. S., Smith E. F., III, Feuerstein G. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ Shock 1992; 37: 124–33
   PubMedGoogle Scholar
• Szebeni J., Wassef N. M., Spielberg H., Rudolph A. S., Alving C. R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Comm 1994; 205: 255–263
   PubMed Web of Science ®Google Scholar
• Wassef N. M., Johnson S. H., Graeber G. M., Swartz G. M., Schultz C. L., Hailey J. R., Johnson A. J., Taylor D. G., Ridgway R. L., Alving C. R. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 1989; 143: 2990–2995
   PubMed Web of Science ®Google Scholar
• Lutz H. U., Stammler P., Jelezarova E., Nater M., Spath P. J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184–193
   PubMed Web of Science ®Google Scholar
• Gabizon A. A., Muggia F. M. Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors. Long-Circulating Liposomes: Old Drugs, New Therapeutics, M. C. Woodle, G. Storm. Landes Bioscience, Austin, TX 1998; 155–174
   Google Scholar
• Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996; 104: 21–50, Suppl 1
   PubMed Web of Science ®Google Scholar
• Kinsky S. C., Haxby J. A., Zopf D. A., Alving C. R., Kinsky C. B. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969; 8: 4149–4158
   PubMed Web of Science ®Google Scholar
• Bodammer G., Vogt W. Actions of anaphylatoxin on circulation and respiration of the guinea pig. Int Arch Allergy Appl Immunol 1967; 32: 417–428
   PubMedGoogle Scholar
• Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C. G., Rabello E., Cass Y., Peretz T. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33: 779–786
   PubMed Web of Science ®Google Scholar
• Zhang L., Plow E. F. Amino acid sequences within the alpha subunit of integrin alpha M beta 2 (Mac-1) critical for specific recognition of C3bi. Biochemistry 1999; 38: 8064–8071
   PubMed Web of Science ®Google Scholar
• Graham I. L., Gresham H. D., Brown E. An immobile subset of plasma membrane CD11b/CD18 (Mac-1) is involved in phagocytosis of targets recognized by multiple receptors. J Immunol 1989; 142: 2352–2358
   PubMed Web of Science ®Google Scholar
• Brown E. J. Complement receptors and phagocytosis. Curr Opin Imm 1991; 3: 176–82
   Web of Science ®Google Scholar
• Jelezarova E., Lutz H. U. Assembly and regulation of the complement amplification loop in blood: the role of C3b-C3b-IgG complexes. Molecular Immunology 1999; 36: 837–842
   PubMed Web of Science ®Google Scholar